{"id":9880,"date":"2024-04-18T15:30:32","date_gmt":"2024-04-18T13:30:32","guid":{"rendered":"https:\/\/www.geicogroup.com\/publicaciones-cientificas\/"},"modified":"2025-11-07T12:34:53","modified_gmt":"2025-11-07T11:34:53","slug":"scientific-publications","status":"publish","type":"page","link":"https:\/\/www.geicogroup.com\/en\/publications\/scientific-publications\/","title":{"rendered":"Scientific Publications"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Scientific Publications<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n \n 2024<\/a>\n \n 2023<\/a>\n \n 2022<\/a>\n \n 2021<\/a>\n\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n \n
\n \n
\n
\n
\n 2024\n <\/div>\n
\n Total Publications: 30\n <\/div>\n \n <\/div>\n \n
\n \n
\n \n
\n
\n \n
\n\n
\n GEICO 69-O\/ANITA\n <\/div>\n \n

\n Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41\/GEICO 69-O\/ANITA Phase III Trial\n <\/p>\n \n

\n Antonio Gonz\u00e1lez-Mart\u00edn et al.\n <\/p>\n \n \n \n <\/div>\n \n

\n\n
\n ENGOT en7\/ Attend\n <\/div>\n \n

\n Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial \n <\/p>\n \n

\n Nicoletta Colombo et al.\n <\/p>\n\n View publication<\/a>\n\n \n <\/div>\n \n

\n\n
\n GEICO 70-C\/BEATcc\n <\/div>\n \n

\n Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial \n <\/p>\n \n

\n Ana Oaknin et al.\n <\/p>\n \n \n \n <\/div>\n \n

\n\n
\n ENGOT en11\n <\/div>\n \n

\n ENGOT-en11\/GOG-3053\/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer\n\n <\/p>\n \n

\n T Van Gorp et al.\n <\/p>\n \n \n\n \n <\/div>\n \n

\n\n
\n ENGOT en11\n\n <\/div>\n \n

\n Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy For Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors <\/p>\n \n

\n Brian M Slomovitz et al.\n <\/p>\n\n \n \n <\/div>\n \n \n <\/div>\n <\/div>\n

\n
\n \n
\n\n
\n ENGOT cx11\n <\/div>\n \n

\n Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial\n <\/p>\n \n

\n Domenica Lorusso et al.\n <\/p>\n \n \n \n <\/div>\n \n

\n\n
\n ENGOT cx12\n <\/div>\n \n

\n Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer \n <\/p>\n \n

\n Ignace Vergote et al.\n <\/p>\n \n \n\n \n <\/div>\n \n

\n\n
\n ENGOT cx9\n <\/div>\n \n

\n Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer\n <\/p>\n \n

\n Kosei Hasegawa et al.\n <\/p>\n \n \n \n <\/div>\n \n

\n\n
\n ENGOT en20\n <\/div>\n \n

\n ENGOT-EN20\/GOG-3083\/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design\n <\/p>\n \n

\n Ignace Vergote et al.\n <\/p>\n \n \n\n \n <\/div>\n \n

\n\n
\n ENGOT en5\/Siendo\n\n <\/div>\n \n

\n Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5\/GOG-3055\/SIENDO study \n <\/p>\n \n

\n Makker V et al.\n <\/p>\n\n \n \n <\/div>\n \n <\/div>\n \n <\/div>\n

\n
\n \n
\n\n
\n ENGOT en9\n <\/div>\n \n

\n \u201cFirst-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomised, Open-Label, Phase 3 Trial\u201d\n <\/p>\n \n

\n et al.\n <\/p>\n \n \n \n <\/div>\n \n

\n\n
\n GEICO 105-O\n <\/div>\n \n

\n Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study \n <\/p>\n \n

\n Mar\u00eda Jes\u00fas Rubio et al.\n <\/p>\n \n \n Ver publicacion\n <\/a>\n\n \n <\/div>\n \n

\n\n
\n GEICO 148-R\/How long is long enough?\n <\/div>\n \n

\n How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes\n <\/p>\n \n

\n Lucy Haggstrom et al.\n <\/p>\n \n \n \n <\/div>\n \n

\n\n
\n ENGOT ov76\/ Gloriosa\n <\/div>\n \n

\n Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FR\u03b1-high platinum-sensitive ovarian cancer\n <\/p>\n \n

\n David M O'Malley et al.\n <\/p>\n \n \n\n \n <\/div>\n \n

\n\n
\n ENGOT ov39\/Imagyn 050\n\n <\/div>\n \n

\n The association of histopathologic features after neoadjuvant chemo-immunotherapy with clinical outcome: Sub-analyses from the randomized double-blinded, placebo-controlled, Phase III IMagyn050\/GOG3015\/ENGOT-ov39 study\n <\/p>\n \n

\n Paulette Mhawech-Fauceglia et al.\n <\/p>\n\n \n \n <\/div>\n \n <\/div>\n <\/div>\n

\n
\n \n
\n\n
\n ENGOT ov25\/Paola 1\n <\/div>\n \n

\n Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1\/ENGOT-ov25 trial\n <\/p>\n \n

\n Domenica Lorusso et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n ENGOT ov25\/Paola 1\n <\/div>\n \n

\n Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations\n <\/p>\n \n

\n Philip C Schouten et al.\n <\/p>\n \n\n \n <\/div>\n \n

\n\n
\n ENGOT ov25\/Paola 1\n <\/div>\n \n

\n Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer\n <\/p>\n \n

\n Romain Boidot et al.\n <\/p>\n \n \n \n <\/div>\n \n

\n\n
\n ENGOT ov26\/PRIMA\n <\/div>\n \n

\n Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial\n <\/p>\n \n

\n B J Monk et al.\n <\/p>\n \n \n\n \n <\/div>\n \n

\n\n
\n ENGOT ov26\/PRIMA\n\n <\/div>\n \n

\n Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA\/ENGOT-OV26\/GOG-3012\n <\/p>\n \n

\n Mitchell R Kamrava et al.\n <\/p>\n\n \n \n <\/div>\n \n <\/div>\n <\/div>\n

\n
\n\n
\n\n
\n ENGOT ov26\/PRIMA\n <\/div>\n \n

\n Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer\n <\/p>\n \n

\n Bradley J Monk et al.\n <\/p>\n \n <\/div>\n \n

\n\n
\n ENGOT ov26\/PRIMA\n <\/div>\n \n

\n Tolerability of the niraparib individualized starting dose in the PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib first-line maintenance therapy\n <\/p>\n \n

\n Christof Vulsteke et al.\n <\/p>\n \n <\/div>\n \n

\n\n
\n ENGOT ov26\/PRIMA\n <\/div>\n \n

\n Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA\/ENGOT-OV26\/GOG-3012 study\n <\/p>\n \n

\n Whitney S Graybill et al.\n <\/p>\n \n\n \n <\/div>\n \n

\n\n
\n ENGOT ov26\/PRIMA\n <\/div>\n \n

\n Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial\n <\/p>\n \n

\n Giorgio Valabrega et al.\n <\/p>\n \n \n \n <\/div>\n \n

\n\n
\n ENGOT ov26\/PRIMA\n <\/div>\n \n

\n Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary\n <\/p>\n \n

\n Antonio Gonz\u00e1lez-Mart\u00edn et al.\n <\/p>\n \n \n\n \n <\/div>\n \n <\/div>\n <\/div>\n

\n
\n\n
\n\n
\n ENGOT ov26\/PRIMA\n <\/div>\n \n

\n Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA\/ENGOT-OV26\/GOG-3012 trial\n <\/p>\n \n

\n Bhavana Pothuri et al.\n <\/p>\n \n <\/div>\n \n

\n\n
\n ENGOT ov81\/Ramp 301\n <\/div>\n \n

\n GOG-3097\/ENGOT-ov81\/GTG-UK\/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer\n <\/p>\n \n

\n Rachel Grisham et al.\n <\/p>\n \n <\/div>\n \n

\n\n
\n Consenso GCIG\n <\/div>\n \n

\n How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting\n <\/p>\n \n

\n Jalid Sehouli et al.\n <\/p>\n \n\n \n <\/div>\n \n

\n\n
\n ENGOT en3\/Paleo\n <\/div>\n \n

\n Palbociclib plus letrozole in estrogen receptor-positive advanced\/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3\/PALEO trial\n <\/p>\n \n

\n Mansoor R. Mirza et al.\n <\/p>\n \n \n \n <\/div>\n \n

\n\n
\n ENGOT ov25\/Paola 1\n <\/div>\n \n

\n Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1\/ENGOT-ov25 trial\n <\/p>\n \n

\n P. Harter et al.\n <\/p>\n \n \n\n \n <\/div>\n \n <\/div>\n <\/div>\n <\/div>\n\n

<\/div>\n\n
<\/div>\n
<\/div>\n\n <\/div>\n \n <\/div>\n \n <\/div>\n\n
\n \n
\n
\n
\n 2023\n <\/div>\n
\n Total Publications: 32\n <\/div>\n \n <\/div>\n \n
\n \n
\n \n
\n
\n \n
\n\n
\n ENGOT-ov57\/AGO ovar 28\n <\/div>\n \n

\n AGO-OVAR 28\/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial \n <\/p>\n \n

\n Florian Heitz et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n ENGOT-ov29\/Atalante\n <\/div>\n \n

\n Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE\/ENGOT-ov29 Trial \n <\/p>\n \n

\n Jean-Emmanuel Kurtz et al.\n <\/p>\n\n View publication<\/a>\n\n \n <\/div>\n \n

\n\n
\n GEICO 60-O\/Borneo\n <\/div>\n \n

\n The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer\u2014A GEICO Study \n <\/p>\n \n

\n Antonio Fern\u00e1ndez-Serra et al.\n <\/p>\n \n \n Ver publicacion\n <\/a>\n \n <\/div>\n \n

\n\n
\n ENGOT en10\/DUO-E\n <\/div>\n \n

\n Durvalumab Plus Carboplatin\/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial \n <\/p>\n \n

\n Shannon N Westin et al.\n <\/p>\n \n View publication<\/a>\n\n \n <\/div>\n \n

\n\n
\n ENGOT cx1\n <\/div>\n \n

\n Randomised phase II BGOG\/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer\n <\/p>\n \n

\n I Vergote et al.\n <\/p>\n\n View publication<\/a>\n \n <\/div>\n \n \n <\/div>\n <\/div>\n

\n
\n \n
\n\n
\n ENGOT-ov40 \/Expression VI\n <\/div>\n

\n Side effects from cancer therapies and patients\u2019 perspective of 1,044 long-term ovarian cancer survivors: Results of Expression VI \u2013 Carolin meets HANNA \u2013 Holistic Analysis of Long-term survival with Ovarian Cancer: International NOGGO, ENGOT, GCIG survey\n <\/p>\n \n

\n Hannah Woopen et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n GUIAS Clinicas \n\n <\/div>\n \n

\n FIGO staging of endometrial cancer: 2023\n <\/p>\n \n

\n Jonathan S Berek et al.\n <\/p>\n \n View publication<\/a>\n\n <\/div>\n \n

\n\n
\n ENGOT-ov5\/Inovatyon\n\n <\/div>\n \n

\n INOVATYON\/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin\/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin\/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line \n <\/p>\n \n

\n N Colombo et al.\n <\/p>\n \n View publication<\/a>\n\n <\/div>\n \n

\n\n
\n ENGOT-ov11\/MILO\n <\/div>\n \n

\n Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO\/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer\n <\/p>\n \n

\n Rachel N Grisham et al.\n <\/p>\n \n View publication<\/a>\n\n <\/div>\n \n

\n\n
\n GEICO 89-T\/MINOVA\n <\/div>\n \n

\n Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T\/MINOVA study)\n <\/p>\n \n

\n Beatriz Tavira et al.\n <\/p>\n\n View publication<\/a>\n\n <\/div>\n \n

\n\n
\n EGOT ov27\/MORAB 003011\n\n <\/div>\n \n

\n Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer\n <\/p>\n \n

\n Thomas J Herzog et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n <\/div>\n \n <\/div>\n

\n
\n \n
\n\n
\n ENGOT ov63\/NIRVANA\n\n <\/div>\n

\n NIRVANA-1: maintenance therapy with niraparib versus niraparib-bevacizumab in patients with advanced ovarian cancer\n <\/p>\n \n

\n Syrine Sghaier et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n ENGOT ov38\/Oreo \n <\/div>\n \n

\n Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO\/ENGOT-ov38): a phase IIIb trial\n <\/p>\n \n

\n E Pujade-Lauraine et al.\n <\/p>\n \n View publication<\/a>\n\n <\/div>\n \n

\n\n
\n ENGOT ov 25\/Paola 1\n\n <\/div>\n \n

\n Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged \u226565 years from the PAOLA-1\/ENGOT-ov25 trial\n <\/p>\n \n

\n Renaud Sabatier et al.\n <\/p>\n\n View publication<\/a>\n\n <\/div>\n \n

\n\n
\n ENGOT ov 25\/Paola 1\n\n <\/div>\n \n

\n Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial\n <\/p>\n \n

\n I. Ray-Coquard et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n ENGOT ov 25\/Paola 1\n\n <\/div>\n \n

\n Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1\/ENGOT-ov25 Trial\n <\/p>\n \n

\n Eric Pujade-Lauraine et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n ENGOT ov 25\/Paola 1\n\n <\/div>\n \n

\n Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1\/ENGOT-ov25 trial subgroup exploratory analysis\n <\/p>\n \n

\n S I Labidi-Galy et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n <\/div>\n <\/div>\n

\n
\n \n
\n\n
\n ENGOT ov 25\/Paola 1\n\n <\/div>\n \n

\n PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1\/ENGOT-ov25 trial\n <\/p>\n\n

\n Liselore Loverix et al.\n <\/p>\n\n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n ENGOT ov 25\/Paola 1\n\n <\/div>\n \n

\n Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer\n <\/p>\n\n

\n Rapha\u00ebl Leman et al.\n <\/p>\n\n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n ENGOT ov 25\/Paola 1\n <\/div>\n \n

\n Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1\/ENGOT-OV25 phase-III trial\n <\/p>\n\n

\n Celine Callens et al.\n <\/p>\n\n View publication<\/a>\n\n <\/div>\n \n

\n\n
\n ENGOT ov 25\/Paola 1\n <\/div>\n \n

\n Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1\/ENGOT-ov25 trial\n <\/p>\n\n

\n Domenica Lorusso et al.\n <\/p>\n\n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n ENGOT ov 25\/Paola 1\n <\/div>\n \n

\n Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation\n <\/p>\n \n

\n Eva-Maria Willing et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n ENGOT ov 25\/Paola 1\n <\/div>\n \n

\n Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma\n <\/p>\n \n

\n Yann Christinat et al\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n <\/div>\n <\/div>\n

\n
\n \n
\n\n
\n ENGOT ov26\/PRIMA\n <\/div>\n \n

\n Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer\n <\/p>\n \n

\n Antonio Gonz\u00e1lez-Mart\u00edn et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n ENGOT ov26\/PRIMA\n <\/div>\n \n

\n Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial\n <\/p>\n \n

\n Mansoor R Mirza et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n ENGOT ov26\/PRIMA\n <\/div>\n \n

\n Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA\/ENGOT-ov26\/GOG-3012 trial: challenges and solutions\n <\/p>\n \n

\n Thomas J Herzog et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n GEICO 1201-T\/RECLAMO\n <\/div>\n \n

\n The Prognostic Significance of Tumor-Infiltrating Lymphocytes, PD-L1, BRCA Mutation Status and Tumor Mutational Burden in Early-Stage High-Grade Serous Ovarian Carcinoma\u2014A Study by the Spanish Group for Ovarian Cancer Research (GEICO)\n <\/p>\n \n

\n David Pizarro et al.\n <\/p>\n\n View publication<\/a>\n\n <\/div>\n \n

\n\n
\n GEICO 88-R\/Registro Niraparib\n <\/div>\n \n

\n Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme\n <\/p>\n \n

\n Juan F.Cueva et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n GEICO 87-R\/Registro Rucaparib \n <\/div>\n \n

\n Rucaparib for PARP inhibitor-pretreated ovarian cancer: A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program\n <\/p>\n \n

\n Alfonso Yubero et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n <\/div>\n <\/div>\n

\n
\n \n
\n\n
\n GEICO 1601\/Rolando\n <\/div>\n \n

\n Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601\n <\/p>\n \n

\n Jos\u00e9 Alejandro Perez-Fidalgo et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n ENGOT-en5\/SIENDO\n <\/div>\n \n

\n Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer\n <\/p>\n \n

\n Ignace Vergote et al.\n <\/p>\n \n View publication<\/a>\n\n <\/div>\n \n

\n\n
\n Statement\n <\/div>\n \n

\n Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer\n <\/p>\n \n

\n Philipp Harter et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n <\/div>\n <\/div>\n <\/div>\n\n

\n <\/div>\n\n
<\/div>\n
<\/div>\n\n <\/div>\n \n <\/div>\n \n <\/div>\n\n
\n \n
\n \n
\n
\n 2022\n <\/div>\n
\n Total Publications: 17\n <\/div>\n <\/div>\n \n
\n \n
\n \n
\n
\n \n
\n\n
\n GEICO \/ATOMICC\n <\/div>\n \n

\n ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation\n <\/p>\n \n

\n Carmen Garcia-Duran et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n GEICO 60-O\/Borneo\n <\/div>\n \n

\n Laboratory Cross-Comparison and Ring Test Trial for Tumor BRCA Testing in a Multicenter Epithelial Ovarian Cancer Series: The BORNEO GEICO 60-0 Study\n <\/p>\n \n

\n Zaida Garcia-Casado et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n ENGOT en9\/LEAP-001\n <\/div>\n \n

\n Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9\/LEAP-001.\n <\/p>\n \n

\n Marth C et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n ENGOT cx9\/EMPOWER CERVICAL 1\n <\/div>\n \n

\n Survival with Cemiplimab in Recurrent Cervical Cancer.\n <\/p>\n \n

\n Tewari et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n ENGOT cx9\/EMPOWER CERVICAL 1\n <\/div>\n \n

\n EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer\n <\/p>\n \n

\n Ana Oaknin et al.\n <\/p>\n \n View publication<\/a>\n\n <\/div>\n \n

\n\n
\n ENGOT ov16\/NOVA\n <\/div>\n \n

\n Ad hoc Analysis of the Phase III ENGOT-OV16\/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects\n <\/p>\n \n

\n Mansoor Raza Mirza et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n <\/div>\n <\/div>\n

\n
\n \n
\n\n
\n GCIG consensus\n <\/div>\n \n

\n Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup\n <\/p>\n \n

\n Ignace Vergote et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n GCIG consensus\n <\/div>\n \n

\n GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: A position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee\n <\/p>\n \n

\n H Woopen et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n ENGOT ov 25\/Paola 1\n <\/div>\n \n

\n Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1\/ENGOT-ov25 trial\n <\/p>\n \n

\n Harter P et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n ENGOT ov 25\/Paola 1\n <\/div>\n \n

\n Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1\/ENGOT-ov25 trial\n <\/p>\n \n

\n Antonio Gonz\u00e1lez-Mart\u00edn et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n ENGOT ov26\/PRIMA\n <\/div>\n \n

\n Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA\/ENGOT-OV26\/GOG-3012 study\n <\/p>\n \n

\n Roisin E O'Cearbhaill et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n <\/div>\n <\/div>\n

\n
\n \n
\n\n
\n ENGOT ov26\/PRIMA\n <\/div>\n \n

\n Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial\n <\/p>\n \n

\n Maria-Pilar Barretina-Ginesta et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n GEICO 81-T\/Registro GEICO\n <\/div>\n \n

\n Prospective Real-World Gynaecological Cancer Clinical Registry with Associated Biospecimens: A Collaborative Model to Promote Translational Research between GEICO and the Spanish Biobank Network\n <\/p>\n \n

\n L\u00f3pez-Guerrero et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n GEICO 87-R\/Registro Rucaparib\n <\/div>\n \n

\n Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain - A GEICO study\n <\/p>\n \n

\n Alfonso Yubero et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n ENGOT ov 21\/SOLO 2\n <\/div>\n \n

\n The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2\/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.\n <\/p>\n \n

\n Francis KE et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n ENGOT ov 21\/SOLO 2\n <\/div>\n \n

\n Efficacy and safety of olaparib according to age in BRCA1\/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2\/ENGOT-Ov21 study.\u00a0\n <\/p>\n \n

\n Trillsch F et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n <\/div>\n <\/div>\n

\n
\n \n
\n\n
\n ENGOT ov 21\/SOLO 2\n <\/div>\n \n

\n Efficacy of subsequent chemotherapy for patients with BRCA1\/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2\/ENGOT Ov-21 trial\n <\/p>\n \n

\n J S Frenel et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n <\/div>\n <\/div>\n\n\n <\/div>\n\n

\n <\/div>\n\n
<\/div>\n
<\/div>\n\n <\/div>\n \n \n <\/div>\n \n <\/div>\n\n
\n \n
\n \n
\n
\n 2021\n <\/div>\n
\n Total Publications: 10\n <\/div>\n <\/div>\n \n
\n \n
\n \n
\n
\n \n
\n\n
\n ENGOT ov41\/GEICO 69-O\/Anita\n <\/div>\n \n

\n A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41\/GEICO 69-O\/ANITA Trial\n <\/p>\n \n

\n Gonzalez Martin A et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n

\n\n
\n ENGOT ov45\/Athena\n <\/div>\n \n

\n ATHENA (GOG-3020\/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.\n <\/p>\n \n

\n Monk BJ et al\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n

\n\n
\n ENGOT cx6\/Innova TV 204\n <\/div>\n \n

\n Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study\n <\/p>\n \n

\n Coleman RL et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n

\n\n
\n ENGOT ov39\/Imagyn 050\n <\/div>\n \n

\n Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050\/GOG 3015\/ENGOT-OV39)\n <\/p>\n \n

\n Kathleen N Moore et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div> \n

\n\n
\n ENGOT ov 25\/Paola 1\n <\/div>\n \n

\n Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1\/ENGOT-ov25 trial.\n <\/p>\n \n

\n Fujiwara K et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n <\/div>\n <\/div>\n \n

\n
\n\n
\n\n
\n ENGOT ov 25\/Paola 1\n <\/div>\n \n

\n Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1\/ENGOT-ov25 Trial.\u00a0\n <\/p>\n \n

\n Callens C et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n GEICO 1601\/Rolando\n <\/div>\n \n

\n Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase\u00a0II trial (ROLANDO study).\n <\/p>\n \n

\n Perez-Fidalgo JA et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n SOLO 1\n <\/div>\n \n

\n Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.\n <\/p>\n \n

\n Banerjee S et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n SOLO 1\/Paola 1\n <\/div>\n \n

\n Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1\/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.\n <\/p>\n \n

\n Vergote I et al.\n <\/p>\n \n View publication<\/a>\n \n <\/div>\n \n

\n\n
\n ENGOT ov 21\/SOLO 2\n <\/div>\n \n

\n Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial\n <\/p>\n \n

\n Andr\u00e9s Poveda et al.\n <\/p>\n \n View publication<\/a>\n\n <\/div>\n \n <\/div>\n <\/div>\n\n <\/div>\n\n

\n <\/div>\n\n
<\/div>\n
<\/div>\n\n <\/div>\n \n \n <\/div>\n \n <\/div>\n\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Scientific Publications 2024 2023 2022 2021 2024 Total Publications: 30 GEICO 69-O\/ANITA Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41\/GEICO 69-O\/ANITA Phase III Trial Antonio Gonz\u00e1lez-Mart\u00edn et al. ENGOT en7\/ Attend Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, … Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":9884,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"template-profesional.php","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-9880","page","type-page","status-publish"],"_links":{"self":[{"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/pages\/9880","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/comments?post=9880"}],"version-history":[{"count":5,"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/pages\/9880\/revisions"}],"predecessor-version":[{"id":10093,"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/pages\/9880\/revisions\/10093"}],"up":[{"embeddable":true,"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/pages\/9884"}],"wp:attachment":[{"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/media?parent=9880"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}